

Union Calendar No. 413

116TH CONGRESS
2^D SESSION

H. R. 4866

[Report No. 116-513]

To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

OCTOBER 28, 2019

Mr. PALLONE (for himself and Mr. GUTHRIE) introduced the following bill;
which was referred to the Committee on Energy and Commerce

SEPTEMBER 17, 2020

Additional sponsor: Ms. SPANBERGER

SEPTEMBER 17, 2020

Reported with an amendment; committed to the Committee of the Whole
House on the State of the Union and ordered to be printed

[Strike out all after the enacting clause and insert the part printed in italic]

[For text of introduced bill, see copy of bill as introduced on October 28, 2019]

A BILL

To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 *This Act may be cited as the “National Centers of Ex-*
5 *cellence in Continuous Pharmaceutical Manufacturing Act*
6 *of 2020”.*

7 **SEC. 2. NATIONAL CENTERS OF EXCELLENCE IN CONTIN-**
8 **UOUS PHARMACEUTICAL MANUFACTURING.**

9 *(a) IN GENERAL.—Section 3016 of the 21st Century*
10 *Cures Act (21 U.S.C. 399h) is amended to read as follows:*

11 **“SEC. 3016. NATIONAL CENTERS OF EXCELLENCE IN CON-**
12 **TINUOUS PHARMACEUTICAL MANUFAC-**
13 **TURING.**

14 *“(a) IN GENERAL.—The Secretary of Health and*
15 *Human Services, acting through the Commissioner of Food*
16 *and Drugs—*

17 *“(1) shall solicit and, beginning not later than*
18 *one year after the date of enactment of the National*
19 *Centers of Excellence in Continuous Pharmaceutical*
20 *Manufacturing Act of 2020, receive requests from in-*
21 *stitutions of higher education to be designated as a*
22 *National Center of Excellence in Continuous Pharma-*
23 *ceutical Manufacturing (in this section referred to as*
24 *a ‘National Center of Excellence’) to support the ad-*

1 *vancement and development of continuous manufac-*
2 *turing; and*

3 *“(2) shall so designate any institution of higher*
4 *education that—*

5 *“(A) requests such designation; and*

6 *“(B) meets the criteria specified in sub-*
7 *section (c).*

8 *“(b) REQUEST FOR DESIGNATION.—A request for des-*
9 *ignation under subsection (a) shall be made to the Secretary*
10 *at such time, in such manner, and containing such infor-*
11 *mation as the Secretary may require. Any such request*
12 *shall include a description of how the institution of higher*
13 *education meets or plans to meet each of the criteria speci-*
14 *fied in subsection (c).*

15 *“(c) CRITERIA FOR DESIGNATION DESCRIBED.—The*
16 *criteria specified in this subsection with respect to an insti-*
17 *tution of higher education are that the institution has, as*
18 *of the date of the submission of a request under subsection*
19 *(a) by such institution—*

20 *“(1) physical and technical capacity for research*
21 *and development of continuous manufacturing;*

22 *“(2) manufacturing knowledge-sharing networks*
23 *with other institutions of higher education, large and*
24 *small pharmaceutical manufacturers, generic and*

1 *nonprescription manufacturers, contract manufactur-*
2 *ers, and other entities;*

3 *“(3) proven capacity to design and demonstrate*
4 *new, highly effective technology for use in continuous*
5 *manufacturing;*

6 *“(4) a track record for creating and transferring*
7 *knowledge with respect to continuous manufacturing;*

8 *“(5) the potential to train a future workforce for*
9 *research on and implementation of advanced manu-*
10 *facturing and continuous manufacturing; and*

11 *“(6) experience in participating in and leading*
12 *a continuous manufacturing technology partnership*
13 *with other institutions of higher education, large and*
14 *small pharmaceutical manufacturers, generic and*
15 *nonprescription manufacturers, contract manufactur-*
16 *ers, and other entities—*

17 *“(A) to support companies with continuous*
18 *manufacturing in the United States;*

19 *“(B) to support Federal agencies with tech-*
20 *nical assistance, which may include regulatory*
21 *and quality metric guidance as applicable, for*
22 *advanced manufacturing and continuous manu-*
23 *facturing;*

24 *“(C) with respect to continuous manufac-*
25 *turing, to organize and conduct research and de-*

1 *velopment activities needed to create new and*
2 *more effective technology, capture and dissemi-*
3 *nate expertise, create intellectual property, and*
4 *maintain technological leadership;*

5 *“(D) to develop best practices for designing*
6 *continuous manufacturing; and*

7 *“(E) to assess and respond to the workforce*
8 *needs for continuous manufacturing, including*
9 *the development of training programs if needed.*

10 *“(d) TERMINATION OF DESIGNATION.—The Secretary*
11 *may terminate the designation of any National Center of*
12 *Excellence designated under this section if the Secretary de-*
13 *termines such National Center of Excellence no longer meets*
14 *the criteria specified in subsection (c). Not later than 60*
15 *days before the effective date of such a termination, the Sec-*
16 *retary shall provide written notice to the National Center*
17 *of Excellence, including the rationale for such termination.*

18 *“(e) CONDITIONS FOR DESIGNATION.—As a condition*
19 *of designation as a National Center of Excellence under this*
20 *section, the Secretary shall require that an institution of*
21 *higher education enter into an agreement with the Sec-*
22 *retary under which the institution agrees—*

23 *“(1) to collaborate directly with the Food and*
24 *Drug Administration to publish the reports required*
25 *by subsection (g);*

1 “(2) to share data with the Food and Drug Ad-
2 ministration regarding best practices and research
3 generated through the funding under subsection (f);

4 “(3) to develop, along with industry partners
5 (which may include large and small biopharma-
6 ceutical manufacturers, generic and nonprescription
7 manufacturers, and contract manufacturers) and an-
8 other institution or institutions designated under this
9 section, if any, a roadmap for developing a contin-
10 uous manufacturing workforce;

11 “(4) to develop, along with industry partners
12 and other institutions designated under this section,
13 a roadmap for strengthening existing, and developing
14 new, relationships with other institutions; and

15 “(5) to provide an annual report to the Food
16 and Drug Administration regarding the institution’s
17 activities under this section, including a description
18 of how the institution continues to meet and make
19 progress on the criteria listed in subsection (c).

20 “(f) FUNDING.—

21 “(1) IN GENERAL.—The Secretary shall award
22 funding, through grants, contracts, or cooperative
23 agreements, to the National Centers of Excellence des-
24 ignated under this section for the purpose of studying
25 and recommending improvements to continuous man-

1 *ufacturing, including such improvements as may en-*
2 *able the Centers—*

3 *“(A) to continue to meet the conditions*
4 *specified in subsection (e); and*

5 *“(B) to expand capacity for research on,*
6 *and development of, continuing manufacturing.*

7 *“(2) CONSISTENCY WITH FDA MISSION.—As a*
8 *condition on receipt of funding under this subsection,*
9 *a National Center of Excellence shall agree to consider*
10 *any input from the Secretary regarding the use of*
11 *funding that would—*

12 *“(A) help to further the advancement of con-*
13 *tinuous manufacturing through the National*
14 *Center of Excellence; and*

15 *“(B) be relevant to the mission of the Food*
16 *and Drug Administration.*

17 *“(3) AUTHORIZATION OF APPROPRIATIONS.—*
18 *There is authorized to be appropriated to carry out*
19 *this subsection \$80,000,000 for the period of fiscal*
20 *years 2021 through 2025.*

21 *“(4) RULE OF CONSTRUCTION.—Nothing in this*
22 *section shall be construed as precluding a National*
23 *Center for Excellence designated under this section*
24 *from receiving funds under any other provision of*
25 *this Act or any other Federal law.*

1 “(g) *ANNUAL REVIEW AND REPORTS.*—

2 “(1) *ANNUAL REPORT.*—*Beginning not later*
3 *than one year after the date on which the first des-*
4 *ignation is made under subsection (a), and annually*
5 *thereafter, the Secretary shall—*

6 “(A) *submit to Congress a report describing*
7 *the activities, partnerships and collaborations,*
8 *Federal policy recommendations, previous and*
9 *continuing funding, and findings of, and any*
10 *other applicable information from, the National*
11 *Centers of Excellence designated under this sec-*
12 *tion; and*

13 “(B) *make such report available to the pub-*
14 *lic in an easily accessible electronic format on*
15 *the website of the Food and Drug Administra-*
16 *tion.*

17 “(2) *REVIEW OF NATIONAL CENTERS OF EXCEL-*
18 *LENCE AND POTENTIAL DESIGNEES.*—*The Secretary*
19 *shall periodically review the National Centers of Ex-*
20 *cellence designated under this section to ensure that*
21 *such National Centers of Excellence continue to meet*
22 *the criteria for designation under this section.*

23 “(3) *REPORT ON LONG-TERM VISION OF FDA*
24 *ROLE.*—*Not later than 2 years after the date on*
25 *which the first designation is made under subsection*

1 (a), the Secretary, in consultation with the National
2 Centers of Excellence designated under this section,
3 shall submit a report to the Congress on the long-term
4 vision of the Department of Health and Human Serv-
5 ices on the role of the Food and Drug Administration
6 in supporting continuous manufacturing, including—

7 “(A) a national framework of principles re-
8 lated to the implementation and regulation of
9 continuous manufacturing;

10 “(B) a plan for the development of Federal
11 regulations and guidance for how advanced
12 manufacturing and continuous manufacturing
13 can be incorporated into the development of
14 pharmaceuticals and regulatory responsibilities
15 of the Food and Drug Administration; and

16 “(C) appropriate feedback solicited from the
17 public, which may include other institutions,
18 large and small biopharmaceutical manufactur-
19 ers, generic and nonprescription manufacturers,
20 and contract manufacturers.

21 “(h) *DEFINITIONS.*—In this section:

22 “(1) *ADVANCED MANUFACTURING.*—The term
23 ‘advanced manufacturing’ means an approach for the
24 manufacturing of pharmaceuticals that incorporates
25 novel technology, or uses an established technique or

1 *technology in a new or innovative way (such as con-*
2 *tinuous manufacturing where the input materials are*
3 *continuously transformed within the process by two*
4 *or more unit operations) that enhances drug quality*
5 *or improves the manufacturing process.*

6 “(2) *CONTINUOUS MANUFACTURING.*—*The term*
7 *‘continuous manufacturing’—*

8 “(A) *means a process where the input mate-*
9 *rials are continuously fed into and transformed*
10 *within the process, and the processed output ma-*
11 *terials are continuously removed from the sys-*
12 *tem; and*

13 “(B) *consists of an integrated process that*
14 *consists of a series of two or more unit oper-*
15 *ations.*

16 “(3) *INSTITUTION OF HIGHER EDUCATION.*—*The*
17 *term ‘institution of higher education’ has the meaning*
18 *given such term in section 101(a) of the Higher Edu-*
19 *cation Act of 1965 (20 U.S.C. 1001(a)).*

20 “(4) *SECRETARY.*—*The term ‘Secretary’ means*
21 *the Secretary of Health and Human Services, acting*
22 *through the Commissioner of Food and Drugs.”.*

23 (b) *TRANSITION RULE.*—*Section 3016 of the 21st Cen-*
24 *tury Cures Act (21 U.S.C. 399h), as in effect on the day*
25 *before the date of the enactment of this section, shall apply*

- 1 *with respect to grants awarded under such section before*
- 2 *such date of enactment.*

Union Calendar No. 413

116TH CONGRESS
2^D SESSION

H. R. 4866

[Report No. 116-513]

A BILL

To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes.

SEPTEMBER 17, 2020

Reported with an amendment; committed to the Committee of the Whole House on the State of the Union and ordered to be printed